Chimeric vaccine antigens against classical swine fever virus
US8409562B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 28, 2007 |
| Grant date | Apr 2, 2013 |
| Priority date | — |
| Expiry date | Apr 19, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24334
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The current invention describes chimeric vaccine antigens against the virus that causes the Classic Swine Fever (CSFV). Such vaccine antigens are based on viral subunits coupled to proteins able to stimulate cellular and humoral immune system. Chimeric antigens can be produced in expression systems that guarantee a correct tertiary structure folding of the chimeric molecules, which constitute the essence of the current invention. The vaccine formulations containing such chimeric antigens induce an early and potent immune response on vaccinated pigs and confer full protection against CSFV. Moreover, the resultant vaccine formulations prevent the viral transmission from sows to their offspring. The chimeric antigens, as well as the resultant vaccine formulations, can be applied in animal health as vaccines for preventive use in swine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.